One Every 20 Minutes: Getting to Zero

A cure for cancer has been the most fervent prayer for far too many patients and their families since cancer was identified as a deadly foe many centuries ago. It remains a holy grail of modern medicine, and researchers and physicians around the world are working day and night to conquer it.

But are we thinking about curing cancer in the right way? Cancer isn’t one disease, and in fact, no two cancers are alike. The biological diversity within single tumors themselves is staggering. In fact, it’s very unlikely that there will ever be one cure for cancer. But there will be cures.

Scientists, in fact, have made tremendous advances against many types of cancer, like prostate cancer, the most common cancer diagnosis in men worldwide after skin cancer. It affects three million men in the U.S. and 14 million worldwide. Diagnosis and treatment have advanced to the point where many men are able to live long and otherwise healthy lives when the cancer is diagnosed early. Despite these significant advances in diagnosing and treating prostate cancer, it takes far too many lives: a man dies of the disease in the U.S. every 20 minutes. About 1 man in 39 will eventually die of prostate cancer.

But researchers are closing in on developing a variety of curative approaches – fueled by a powerful driving force in the Prostate Cancer Foundation (PCF). Founded 23 years ago, PCF funds innovative research and researchers with the potential to make a difference in patients’ lives. Over the past two decades, tremendous advances have been made, driven by PCF’s ability to deliver resources to top scientists and cut through red tape. A multi-pronged approach to curing almost all types of prostate cancer is now within sight of the very scientists PCF is funding.

PCF has already helped advance six medicines that are now available and extending the lives of men living with advanced disease. Research largely funded by PCF has identified 19 prostate cancer genes and make strides each day in developing precision treatments to target these genes. PCF’s goal is to have a range of therapies available that, if used in combination, would dramatically reduce the number of prostate cancer deaths within five years and, quite possibly, in other cancers as well. To get there, PCF has launched Many vs Cancer, a national crowdfunding initiative, aimed at using strength in numbers to power the urgent research needed to fund life-extending, life-saving, curative therapies for prostate cancer.

And we at W2O Group want to be a part of this remarkable effort. Our experience and passion for communicating the best in science and medicine has put us in a position where we believe we can effectively amplify PCF’s mission.

We are proud to have been chosen recently by PCF as their communications agency of record, and are thrilled to support our new colleagues at PCF. But we wanted to do even more, because we see that the goal is within sight: we see the future advances that will help patients live longer and longer.

To that end, we are making a donation of pro-bono staff time to extend the reach of the important work we will be doing together with PCF. We’re excited to be a part of PCF’s efforts to go that last mile for the all too many men and their families being devastated by prostate cancer, and encourage others to join the Many Versus Cancer movement or donate to support these breakthrough efforts.  Together, we are hopeful for the elusive cures nearly within reach.

Emily Poe
Emily Poe
Global Practice Leader, Healthcare Communications